Shares of Stoke Therapeutics sank Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Stoke Therapeutics (STOK – Research Report), with a price ...

T he price trend for Stoke Therapeutics, Inc. (STOK) has been bearish lately and the stock has lost 14.8% over the past week. However, the formation of a hammer chart pattern in its last trading ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

STOK stock opened at $8.26 on Wednesday. The stock has a market capitalization of $437.51 million, a P/E ratio of -3.93 and a beta of 0.99. Stoke Therapeutics has a 52 week low of $5.60 and a 52 ...

With this partnership, Stok’d customers can now connect with Apothecare’s licensed pharmacists, who specialize in integrating cannabis into individualized treatment plans. Whether customers seek ...

TORONTO, March 31, 2025 (GLOBE NEWSWIRE) — Apothecare, a pharmacist-led cannabis consultation service, is collaborating with a growing network of trusted cannabis retailers—including Stok’d ...